Neoantigen – Talk Bio

UbiVac Showcases First ‘Dark Matter’ Cancer Immunotherapy Clinical Data at SITC 2025 Annual Meeting

1 month ago talkbio0Tagged Allogeneic Autophagosome-enriched Vaccine DPV-001, alternatives, anti-PD-1, Clinical Trials, Combined Modality Therapy, Dark color, dark matter, Genome, immunopeptidome, Immunotherapy for cancer, Malignant Head and Neck Neoplasm, Neoantigen, SITC, T-Cell Receptor, UbiVac

UbiVac; DPV-001; cancer immunotherapy; dark matter; dark genome; alternatives neoantigens; T cell receptor (TCR); head and neck cancer; SITC 2025; clinical trial; combination therapy; anti-PD-1; immunopeptidome

Personalized Cancer Vaccine Shows Promise in Preventing Recurrence of Advanced Kidney Cancer

10 months ago talkbio0Tagged cell renal cell carcinoma, Conventional (Clear Cell) Renal Cell Carcinoma, Immunotherapy, Malignant neoplasm of kidney, Neoantigen, personalized cancer, phase 1 trial

personalized cancer vaccine, kidney cancer, clear cell renal cell carcinoma (ccRCC), neoantigen, immunotherapy, cancer recurrence prevention, phase 1 trial

Gritstone’s GRANITE Vaccine Shows Encouraging but Limited Benefit in Metastatic Colorectal Cancer

1 year ago talkbio0Tagged Cancer Vaccines, ctDNA, granite, Gritstone Bio, Immunotherapy, Metastasis from malignant neoplasm of colon and/or rectum, MSS-CRC, Neoantigen, Progression-Free Survival

Gritstone bio, GRANITE, cancer vaccine, metastatic colorectal cancer, MSS-CRC, neoantigen targeting immunotherapy, progression-free survival, ctDNA